Elsevier

Ophthalmology

Volume 108, Issue 11, November 2001, Pages 2116-2121
Ophthalmology

Plaque radiotherapy for retinoblastoma: Long-term tumor control and treatment complications in 208 tumors

https://doi.org/10.1016/S0161-6420(01)00797-7Get rights and content

Abstract

Objective

To evaluate the clinical factors predictive for tumor recurrence and treatment complications in a large series of children who underwent plaque radiotherapy for retinoblastoma.

Design

Retrospective, noncomparative case series.

Participants

The participants included 141 children with retinoblastoma who were managed on the Oncology Service at Wills Eye Hospital with plaque radiotherapy between July 1976 and June 1999.

Main outcome measures

Tumor recurrence and treatment complications.

Results

There were 208 tumors managed with plaque radiotherapy. The mean patient age at plaque treatment was 19 months. Prior treatment to the retinoblastoma of concern was delivered to 148 tumors (71%) and included various combinations of treatments such as intravenous chemoreduction, external beam radiotherapy, laser photocoagulation, thermotherapy, and cryotherapy. For 72 retinoblastomas (35%), more than one therapeutic method had failed to achieve tumor control before the use of plaque radiotherapy. Of the 208 retinoblastomas managed with plaque radiotherapy, Kaplan-Meier estimates of tumor control were 83% at 1 year and 79% at 5 years. Of the 60 tumors treated only with plaque radiotherapy (primary treatment), recurrence at 1 year was 12%. Of the 148 tumors treated after failure of other methods (secondary treatment), specific Kaplan-Meier estimates of tumor recurrence at 1 year was detected in 8% of tumors previously treated with chemoreduction, 25% of tumors previously treated with external beam radiotherapy, 34% tumors previously treated with both chemoreduction and external beam radiotherapy, and 8% of tumors previously treated with laser photocoagulation, thermotherapy, or cryotherapy (methods other than chemoreduction and external beam radiotherapy). Using multivariable analysis, the risks for tumor recurrence included the presence of tumor seeds in the vitreous, presence of subretinal tumor seeds, and increasing patient age. Using Kaplan-Meier estimates, radiation complications at 5 years of follow-up included nonproliferative retinopathy in 27%, proliferative retinopathy in 15%, maculopathy in 25%, papillopathy in 26%, cataract in 31%, glaucoma in 11%, and scleral necrosis in 0%.

Conclusions

Plaque radiotherapy for retinoblastoma provides tumor control in 79% of cases at 5 years of follow-up. It is particularly useful for those tumors that fail treatment with chemoreduction, laser photocoagulation, thermotherapy, and cryotherapy. Tumors in young patients without vitreous or subretinal seeding show the best long-term control.

Section snippets

Materials and methods

The clinical records of all patients with the diagnosis of retinoblastoma managed on the Ocular Oncology Service at Wills Eye Hospital, Philadelphia, Pennsylvania, between July 1976 and June 1999 were reviewed. Clinical data were gathered regarding features of the tumor as well as radiation parameters. These features included age at plaque treatment, type of tumor treated with plaque (retinal tumor, subretinal seeds, vitreous seeds), prior treatment to the tumor of concern (chemoreduction,

Results

Of more than 900 patients with retinoblastoma managed on the Ocular Oncology Service between July 1976 and June 1999, 141 were treated at some time during their course with plaque radiotherapy. The clinical parameters regarding the patients and tumor findings are listed in Table 1. Subretinal fluid was found surrounding 31 tumors (15%). Adjacent active vitreous or subretinal seeds, or both, were found over a mean of 1.3 quadrants (median, 1.0 quadrant) and were included in the radiation

Discussion

Brachytherapy (plaque radiotherapy) is a method of delivering focal irradiation to a tumor in an effort to minimize side effects to the surrounding normal tissue. With regard to the eye, brachytherapy is most often used for intraocular malignancies such as choroidal melanoma and retinoblastoma.11, 20 Brachytherapy for retinoblastoma has been used for many years,7, 8, 12, 13, 21, 22, 23, 24 and, presently, I125 is the most commonly used radioisotope for retinoblastoma. The advantages of

References (28)

  • Shields CL, Meadows AT, Shields JA, et al. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic...
  • R.F Moore et al.

    Retinal gliomata treated by radon seeds

    Br J Ophthalmol

    (1931)
  • H.B Stallard

    Radiotherapy of malignant intra-ocular neoplasms

    Br J Ophthalmol

    (1948)
  • J.A Shields et al.

    Atlas of Intraocular Tumors

    (1999)
  • Cited by (171)

    • Palladium-103 plaque brachytherapy for retinoblastoma: Long term follow up

      2022, American Journal of Ophthalmology Case Reports
      Citation Excerpt :

      Shields et al. reported using a variety of radionuclides: 60Co, 125I, 192Ir and 106Ru as primary treatment for 31 cases and noted local recurrences in 16% at a follow up of 3.5 years.6 In a later study, they reported on 60 tumors treated with 125I plaque radiotherapy, yielding a recurrence rate of 12% at 1 year.11 Similarly, Abouzeid et al. noted a tumor recurrence in 12.5% tumors at 1 year, when106Ru plaque brachytherapy was used as a first- or second-line treatment.8

    • Global retinoblastoma survival and globe preservation: a systematic review and meta-analysis of associations with socioeconomic and health-care factors

      2022, The Lancet Global Health
      Citation Excerpt :

      For the remaining 311 articles, 56 spanned at least 20 years and had no subperiods, with a median duration of 27 years (IQR 22–32).14–69 These articles were included for analysing the associations of socioeconomic and health-care factors but not for time-trend analysis (overall survival and globe salvage across decades) because subperiod data breakdown was not available (figure 1).14–69 Ultimately, 255 articles were entered for time-trend meta-analysis (table 1; appendix pp 23–42).

    • Neonatal Retinoblastoma

      2021, Clinics in Perinatology
    View all citing articles on Scopus

    Supported by the Paul Kayser International Award of Merit in Retina Research, Houston, Texas (JAS); the Macula Foundation, New York, New York (CLS); and the Eye Tumor Research Foundation, Philadelphia, Pennsylvania (CLS).

    View full text